trending Market Intelligence /marketintelligence/en/news-insights/trending/bgkmcql_uvnw1qc4igux3w2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA grants breakthrough therapy designation to Juno's lymphoma drug

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


US FDA grants breakthrough therapy designation to Juno's lymphoma drug

The U.S. FDA granted Juno Therapeutics Inc. and partner Celgene Corp.'s investigational drug JCAR017 a breakthrough therapy designation for the treatment of patients with relapsed/refractory aggressive large B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and certain other lymphomas.

The European Medicines Agency's Committee for Medicinal Products for Human Use and Committee for Advanced Therapies granted JCAR017 access to the priority medicines scheme for relapsed/refractory diffuse large B-cell lymphoma. A study is expected to begin in 2017.

The drug is currently not approved in any country.